论文部分内容阅读
骨髓增生异常综合征(MDS)是造血干细胞的疾病,表现在外周血一、二系或全血细胞减少,骨髓各系表现有病态造血。部分病例可转化为急性白血病。目前,对MDS尚无满意的治疗方法。自发现维生素甲类化合物(Retinoids)能诱导白血病细胞分化、抑制某些癌前病变及肿瘤生长以来,维生素甲类化合物在肿瘤防治上的作用引起了学者们的广泛注意。1980年Honma等观察了维生素甲的衍生物维甲酸(Retinoic acid)对人早幼粒细胞白血病细胞株HL-60的诱导分化作用。1982年Itri等提出维甲酸对MDS及早幼粒细胞白血病有治疗作用。此后,也见有应用维甲酸治疗MDS的报告,有一定的效果。中国医学科学院药物研究所研制的维胺酸(4-Hydroxycarbophenyl,Retinamide,简称RⅡ)经实验证明,对人早幼粒细胞白血病细胞株HL-60也有诱导分化作用,毒副作用远远低于维甲酸。我科自1987年2月开始
Myelodysplastic syndrome (MDS) is a hematopoietic stem cell disease, manifested in peripheral blood mononuclear cells, or pancytopenia, all manifestations of bone marrow dysplasia. Some cases can be transformed into acute leukemia. At present, there is no satisfactory treatment for MDS. Since the discovery of retinoids (Retinoids) can induce the differentiation of leukemia cells and inhibit some precancerous lesions and tumor growth, the role of vitamin A compounds in the prevention and treatment of cancer has drawn the attention of scholars. Honma et al 1980 observed the retinoid retinoid (Retinoic acid) on human promyelocytic leukemia cell line HL-60 induced differentiation. 1982 Itri, etc. proposed retinoic acid on the MDS and promyelocytic leukemia have a therapeutic effect. Since then, there are also reports of treatment with retinoic acid MDS, have some effect. 4-Hydroxycarbophenyl (Retinamide, RⅡ) developed by Institute of Materia Medica, Institute of Materia Medica, Chinese Academy of Medical Sciences, has been proved by experiments to induce differentiation on human promyelocytic leukemia cell line HL-60 with toxicity and side effects much lower than that of retinoic acid . Our department since February 1987